Literature DB >> 19074034

Negative impact of statins on oligodendrocytes and myelin formation in vitro and in vivo.

Steve Klopfleisch1, Doron Merkler, Matthias Schmitz, Sabine Klöppner, Mariann Schedensack, Gunnar Jeserich, Hans H Althaus, Wolfgang Brück.   

Abstract

Statins are widely prescribed drugs in cardiovascular diseases. Recent studies also demonstrated anti-inflammatory and immunomodulatory properties of statins by modulating the activity of small GTPases. Statins are thus considered as potential therapeutic drug for the inflammatory demyelinating disease multiple sclerosis (MS). However, little is known about the effects of statins on myelin-forming oligodendrocytes. Here, we show that statins hamper process and myelin formation in vitro by interfering with Ras and Rho signaling in mature oligodendrocytes and provide evidence that statins impair ongoing remyelination in vivo. Our findings may have significant implications for the application of statins in MS patients and in other demyelinating diseases of the CNS.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19074034      PMCID: PMC6671750          DOI: 10.1523/JNEUROSCI.2765-08.2008

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  28 in total

1.  Statins and memory loss: An Australian experience.

Authors:  Anna I Jamolowicz; Huei-Yang Chen; Peter K Panegyres
Journal:  Australas Med J       Date:  2015-03-31

2.  Association between statin use and Bell's palsy: a population-based study.

Authors:  Shih-Han Hung; Li-Hsuan Wang; Herng-Ching Lin; Shiu-Dong Chung
Journal:  Drug Saf       Date:  2014-09       Impact factor: 5.606

Review 3.  Peroxisome proliferator-activated receptor γ (PPARγ): A master gatekeeper in CNS injury and repair.

Authors:  Wei Cai; Tuo Yang; Huan Liu; Lijuan Han; Kai Zhang; Xiaoming Hu; Xuejing Zhang; Ke-Jie Yin; Yanqin Gao; Michael V L Bennett; Rehana K Leak; Jun Chen
Journal:  Prog Neurobiol       Date:  2017-10-12       Impact factor: 11.685

4.  Activation of PPAR-γ and PTEN cascade participates in lovastatin-mediated accelerated differentiation of oligodendrocyte progenitor cells.

Authors:  Ajaib S Paintlia; Manjeet K Paintlia; Avtar K Singh; John K Orak; Inderjit Singh
Journal:  Glia       Date:  2010-11-01       Impact factor: 7.452

Review 5.  3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the treatment of central nervous system diseases.

Authors:  Joshua Z Willey; Mitchell S V Elkind
Journal:  Arch Neurol       Date:  2010-09

6.  Mutation of 3-hydroxy-3-methylglutaryl CoA synthase I reveals requirements for isoprenoid and cholesterol synthesis in oligodendrocyte migration arrest, axon wrapping, and myelin gene expression.

Authors:  Emily S Mathews; David J Mawdsley; Macie Walker; Jacob H Hines; Marina Pozzoli; Bruce Appel
Journal:  J Neurosci       Date:  2014-02-26       Impact factor: 6.167

7.  Statin therapy inhibits remyelination in the central nervous system.

Authors:  Veronique E Miron; Simone P Zehntner; Tanja Kuhlmann; Samuel K Ludwin; Trevor Owens; Timothy E Kennedy; Barry J Bedell; Jack P Antel
Journal:  Am J Pathol       Date:  2009-04-06       Impact factor: 4.307

8.  Statin Therapy and Risk of Acute Memory Impairment.

Authors:  Brian L Strom; Rita Schinnar; Jason Karlawish; Sean Hennessy; Valerie Teal; Warren B Bilker
Journal:  JAMA Intern Med       Date:  2015-08       Impact factor: 21.873

9.  SWiss Atorvastatin and interferon Beta-1b trial In Multiple Sclerosis (SWABIMS)--rationale, design and methodology.

Authors:  Christian P Kamm; Heinrich P Mattle
Journal:  Trials       Date:  2009-12-14       Impact factor: 2.279

10.  What is the optimal value of the g-ratio for myelinated fibers in the rat CNS? A theoretical approach.

Authors:  Taylor Chomiak; Bin Hu
Journal:  PLoS One       Date:  2009-11-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.